NCT00849511

Melatonin for Migraine Prevention

Melatonin for Migraine Prevention (The MMP-study): A Randomized, Double-blind, Cross-over, Placebo-controlled Study of Melatonin in Prophylactic Treatment of Migraine

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Nordlandssykehuset HF · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The circadian system with its centre in the hypothalamus is involved in migraine pathophysiology. Whether it plays a pivotal role is not clarified. The investigators postulate that a destabilized circadian system may increase migraine attack susceptibility, and that stabilization by supplying melatonin a migraine preventive effect will be achieved. A previous open label study has shown effects that certainly warrant a placebo controlled study.

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	melatonin	Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-09-01
• Completion: 2009-10-01
• First posted: 2009-02-24
• Last updated: 2014-09-25

Locations

2 sites across 1 country: Norway